Pure H2O Bio-Technologies, Inc. (Pink Sheets: PRHB) announced today its receipt of a letter of intent from H.M. Northcutt Corporation, regarding the installation, monitoring and service of the first 100 Hospital Potable Water Disinfection Systems, Model 7000 as described below in Pure H20�s Pilot Program.

H.M. Northcutt Corp, located in Mt. Pleasant, South Carolina, is a company with 33 years of experience specializing in sales, installation and service of innovative water equipment. For additional information visit web-site: www.hmnorthcutt.com

Upon final National Sanitation Foundation (NSF) certification of Pure H20�s integrated Hospital Potable Water Disinfection System, Model 7000, the parties shall enter into a formal agreement detailing the objectives of Pure H20�s Pilot Program, defining the territories of installation in medical facilities within the states of Florida, Georgia and the Carolinas, monitoring and determining replacement and service costs.

In the letter of intent dated May 13, 2009, addressed to Mr. Joseph P. Doxey, President of Pure H20 Bio-Technologies, Inc., Mr. Charlie Northcutt, President of H.M. Northcutt Corp stated, �We are proud of our track record in the water treatment industry. You and your stockholders can rest assured of professional installation and service through the H.M. Northcutt Corporation.

About Pure H20 Bio-Technologies, Inc.

Pure H2O recently completed its bench, kinetic and pre-certification testing of its innovative drinking water treatment system with outstanding results. Mr. Joseph Doxey, President of Pure H2O, stated, �We want to welcome Charlie Northcutt, H.M. Northcutt Corp., Gary Schmidt, Wes Com Capital and Mike N. Brette, J.D. of The Wall Street News Hour to our team of accomplished professionals. I am confident we are building a strong and proven team to accomplish our goal of bringing our Hospital System to market.� The Company was awarded patent #7250111, and has two additional patents pending at this time that are under review with the U.S. Patent and Trademark Office, Washington, D.C.

PILOT PROGRAM: Participant Revenue Sharing Agreement (�PRSA�) for its first 100 manufactured Integrated Hospital Potable Water Disinfections System known as Model 7000.

The Pilot Program is designed to offer an opportunity that benefits all parties involved. It allows the Company to seek additional capital in the form of participants sharing revenues generated from intended lease, rental or purchase agreements; it allows the Company to seek capital through government financial assistance programs for skilled workers, equipment and expansion. It allows the commencement of manufacturing the first 100 Hospital Systems; allows expediency in regard to our micro�team, engineering team, laboratories, government agencies and officials; it allows a financial opportunity for investors to receive conservative returns and allows the Company to absorb expenses associated with NSF Certification without further dilution to shareholders.

Visit our web-site at www.pureh20biotech.com.

The �Participant Revenue Sharing Agreement� (�PRSA�) can be viewed on the Company�s web-site under title �Pilot Program�. Further information has been uploaded for the serious professional including (i) Technical Production Video, (ii) Written Video Script, (iii) Question & Answers produced by Special Report T.V. and (iv) Description of the Hospital Potable Water Disinfection System, Model 7000.

To learn more about our Pilot Program or for additional questions call Mr. Gary Schmidt at Wescom Capital, Inc.�(206) 420-5710 or write to Mr. Schmidt via email at gls@wescomcapital.com.

The Company will be announcing its progress on a regular basis and will continue to keep its shareholders apprised through these stages. Visit our web-site for updates and to view our Pilot Program at www.pureh20biotech.com.

The foregoing press release contains forward-looking statements that can be identified by such terminology as "expects," "potential,� suggests," "may," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to the availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and completion in general. Forward-looking statements speak only as to the date they were made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Pure H2O Bio Technologies (CE) (USOTC:PRHB)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Pure H2O Bio Technologies (CE) Charts.
Pure H2O Bio Technologies (CE) (USOTC:PRHB)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Pure H2O Bio Technologies (CE) Charts.